{
    "organizations": [],
    "uuid": "b9726a1ac66397889f00d77a36c7061b559916e3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-advaxis-submits-conditional-maa-fo/brief-advaxis-submits-conditional-maa-for-second-line-metastatic-cervical-cancer-treatment-in-european-union-idUSFWN1Q30ZZ",
    "ord_in_thread": 0,
    "title": "Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Advaxis Inc:\n* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION\n* ADVAXIS INC - COMPANY WILL CONTINUE ASSESSING PARTNERSHIP OPPORTUNITIES FOR POTENTIAL COMMERCIALIZATION OF AXALIMOGENE FILOLISBAC IN EUROPE\n* ADVAXIS- DECIDED TO ALIGN, SIMPLIFY STRATEGY BY USING AXALIMOGENE FILOLISBAC EXCLUSIVELY IN ALL ONGOING AND PLANNED HPV-RELATED CANCER CLINICAL TRIALS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T21:44:00.000+02:00",
    "crawled": "2018-02-14T12:18:13.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "advaxis",
        "inc",
        "advaxis",
        "submits",
        "conditional",
        "marketing",
        "authorization",
        "application",
        "axalimogene",
        "filolisbac",
        "treatment",
        "metastatic",
        "cervical",
        "cancer",
        "european",
        "union",
        "advaxis",
        "inc",
        "company",
        "continue",
        "assessing",
        "partnership",
        "opportunity",
        "potential",
        "commercialization",
        "axalimogene",
        "filolisbac",
        "europe",
        "decided",
        "align",
        "simplify",
        "strategy",
        "using",
        "axalimogene",
        "filolisbac",
        "exclusively",
        "ongoing",
        "planned",
        "cancer",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}